Company intelligence / Profile preview
Kither Biotech
Turin, Turin, Italykitherbiotech.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
KIT2014 has entered Phase 1 clinical trials as of October 2024. The SAD/MAD study is expected to enroll 72 healthy volunteers and will evaluate up to 6 dose levels of KIT2014 delivered via nebulizer versus placebo.[9]
- Therapeutic areas
- PulmonologyRare Diseases
- Modalities
- Small moleculesPeptides
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Kither Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kither Biotech.